| DB ID | MyCo_2935 |
| Title | A retrospective cohort of invasive fusariosis in the era of antimould prophylaxis |
| Year | 2020 |
| PMID | 31231772 |
| Fungal Diseases involved | Invasive fusariosis |
| Associated Medical Condition | None |
| Genus | Fusarium |
| Species | spp. |
| Organism | Fusarium spp. |
| Ethical Statement | The study and the case report form were approved by the local institutional review board and ethics committee (22/18). |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Spain |
| Cohort | During the study period, eight cases of invasive fusariosis werediagnosed (six proven, two probable) in patients with hematologic malignancy |
| Cohort No. | 8 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Assay |
| Analysis Method | FDA Approved -Fungitell Assay |
| ELISA kits | ELISA Kit- Platelia Aspergillus (Platelia Aspergillus EIA; Bio-Rad Laboratories, Bio-Rad, Marnes-la-Coquette, France) |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved -Fungitell Assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
